-

AntiCancer Files Second Lawsuit Against Certis Oncology

SAN DIEGO--(BUSINESS WIRE)--AntiCancer, Inc., a worldwide leader in cancer research and the pioneer of patient-derived mouse models of cancer, announced today it has filed a second lawsuit against Certis Oncology Solutions, Inc.

The companies are locked in a long-running legal dispute over hundreds of “immortalized” patient tumor samples which AntiCancer developed and alleges were stolen by Certis, a controversial startup which was originally founded by AntiCancer.

The new lawsuit seeks a court order requiring Certis to provide shareholder and financial records requested by AntiCancer.

“We are disappointed that Certis continues to stonewall and refuses to provide information that all shareholders are entitled to,” said Robert M. Hoffman, Founder and CEO of AntiCancer. “This behavior is reminiscent of Theranos and raises troubling questions about Certis’ management of the company and its willingness to follow the law. That’s especially concerning at a time when Certis is offering Covid-19 testing to the public, in addition to providing medical advice directly to cancer patients. If Certis is not following the rules and being honest with its own shareholders, how can it be trusted with the public’s health?”

The new lawsuit, filed in San Diego Superior Court, is titled AntiCancer, Inc. v. Certis Oncology, Inc., 37-2020-35454-CU-WM-CTL.

AntiCancer, founded in 1984 and headquartered in San Diego, is the world leader in mouse models of cancer and three-dimensional tumor culture. The company has pioneered the use of these technologies for precision, individualized cancer-patient therapy. AntiCancer performs contract research for the pharmaceutical industry and has published over 1,000 innovative scientific papers. AntiCancer has subsidiaries in Tokyo, Beijing, Nanjing, and Seoul.

Contacts

Qinghong Han, MD.
all@anticancer.com

Industry:

AntiCancer, Inc.

Release Versions
English

Contacts

Qinghong Han, MD.
all@anticancer.com

More News From AntiCancer, Inc.

AntiCancer Inc. Has Received a New Patent That Revolutionizes Individualized Mouse Models of Human Cancer Patients by Increasing the Patient-tumor Establishment Rate in Mice to Close to 100%

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, a...

AntiCancer’s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate predict...

AntiCancer Inc. Scientists Discover the Fundamental Basis of the Malignancy of Cancer

SAN DIEGO--(BUSINESS WIRE)--In a new article appearing in the current issue of the Cell Press scientific journal iScience, AntiCancer Inc. of San Diego has demonstrated that the addiction of cancer to the common amino acid methionine is the basis of the malignancy of cancer. The new article demonstrates that the excess methionine needed by cancer cells for their addiction is used to pathologically modify proteins that control gene expression (called histones), by a process called hyper-methylat...
Back to Newsroom